Ionis Pharmaceuticals (FRA:ISI) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals 3-Year Dividend Growth Rate?

Ionis Pharmaceuticals's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The historical rank and industry rank for Ionis Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

FRA:ISI's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Ionis Pharmaceuticals's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Ionis Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Ionis Pharmaceuticals's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Ionis Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ionis Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's 3-Year Dividend Growth Rate falls into.

Ionis Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Ionis Pharmaceuticals (FRA:ISI) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Ionis Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-1.01
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>

Ionis Pharmaceuticals (FRA:ISI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (FRA:ISI) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

IONS:USA IONS:Mexico

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (FRA:ISI) Headlines

No Headlines